At a glance
ClinicalIndex Comparison RecordN/ACompleted· 30 enrolled
Drug / intervention
transurethral resection of the prostateprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia: A Possible Marker of Progression and Response to Medical Therapy
In Brief
An observational study evaluating transurethral resection of the prostate for BPH. Completed, enrolled 30 participants across 1 site.
Detailed Summary
We hypothesize that the absolute or relative serum or urine levels of the urokinase plasminogen activator system, including uPA, uPAR and PAI-1,2 (inhibitors of the uPAR/uPA complex), are associated with inflammation in prostatic tissue.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBPH
CountriesCanada
Collaborators--
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2006
First PostedDec 2006
Primary CompletionFeb 2008
Study CompletionJan 2012
TodayJul 2026
First PostedDec 5, 2006
Enrollment StartNov 1, 2006
Primary CompletionFeb 1, 2008
Study CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 19.6 years ago
Interventions
transurethral resection of the prostateprocedure
resection of prostate